In The Zone is a lice Read more [...]
Our vision at CanniMed® Ltd. is to help people with chronic and terminal illnesses improve their quality of life when conventional medicine just isn’t enough. We focus on producing pharmaceutical-grade cannabis through research and development as well as through collaborations with external partners, including academic institutions and healthcare professionals.
Patient safety is paramount at CanniMed® Ltd.
Our pharmaceutical-grade cannabis products are grown in accordance with rigorous health and safety standards and produced under Good Manufacturing Practices (GMP) helping to ensure a safe and reliable product. GMP is the criteria used to manufacture all pharmaceuticals in Canada.
Ongoing research into the efficacy of medical cannabis is critical and at CanniMed we are taking a very active role in this endeavour.
To date, the pharmaceutical-grade cannabis produced by Prairie Plant Systems, under contract with CanniMed® Ltd., has been used in published clinical trial results to demonstrate the efficacy of smoked cannabis for chronic pain.¹
Our clinical trial program is robust and includes ongoing studies in patients with osteoarthritis of the knee, Tourette’s Syndrome and juvenile epilepsy, to name a few.
¹ MA Ware, T Wang, S Shapiro, A Robinson et al.(2010) “Smoked Cannabis for Chronic Pain: a Randomized Controlled Trial,” Canadian Medical Association Journal (CMAJ). 182:E694-E701.